Avirup A Bose

US Patent:

20100016387, Jan 21, 2010

Filed:

Dec 10, 2007

Appl. No.:

12/518551

Inventors:

Avirup Bose - Marlborough MA, US
Thomas Edward Hughes - Concord MA, US

International Classification:

A61K 31/428
A61K 31/423
A61K 31/4184
A61K 31/403

US Classification:

514367, 514375, 514394, 514417

Abstract:

Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound.

US Patent:

20230060422, Mar 2, 2023

Filed:

Dec 18, 2020

Appl. No.:

17/786491

Inventors:

- Basel, CH
- South San Francisco, US
Avirup BOSE - Marlborough MA, US
Jacob CHA - South San Francisco CA, US
Nicole COOPER - Oakland CA, US
Darren FINKELSTEIN - South San Francisco CA, US
Linda GREENBAUM - Florham Park NJ, US
Johannes HULL - San Francisco CA, US
Susan Caroline KIRKLAND - Surrey, GB
Katerina LEFTHERIS - San Mateo CA, US
Maureen REILLY - Burlingame CA, US
Peter TARSA - Marshfield MA, US
Chinweike UKOMADU - Chestnut Hill MA, US

International Classification:

A61K 31/4162
A61K 31/4375
A61K 31/7048
A61K 45/06
A61P 1/16

Abstract:

The invention provides a pharmaceutical combination including an αvβintegrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The additional therapeutic agent may be an SGLT1/2 inhibitor, among a diverse selection of agents. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) nonanoic acid (Compound 1) and at least one additional therapeutic agent.

US Patent:

20230055657, Feb 23, 2023

Filed:

Dec 18, 2020

Appl. No.:

17/786499

Inventors:

- Basel, CH
- South San Francisco CA, US
Avirup BOSE - Marlborough MA, US
Jacob CHA - South San Francisco CA, US
Nicole COOPER - Oakland CA, US
Darren FINKELSTEIN - South San Francisco CA, US
Linda GREENBAUM - Florham Park NJ, US
Johannes HULL - San Francisco CA, US
Susan Caroline KIRKLAND - Surrey, GB
Katerina LEFTHERIS - San Mateo CA, US
Maureen REILLY - Burlingame CA, US
Peter TARSA - Marshfield MA, US
Chinweike UKOMADU - Chestnut Hill MA, US

International Classification:

A61K 31/46
A61K 31/4353
A61P 1/16

Abstract:

The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).

US Patent:

20210000964, Jan 7, 2021

Filed:

Jun 1, 2020

Appl. No.:

16/889201

Inventors:

- Basel, CH
Avirup BOSE - Marlborough MA, US
Alexandra Marshall BRUCE - Cambridge MA, US
Alokesh DUTTAROY - Marlborough MA, US
Chikwendu IBEBUNJO - Newton MA, US
Aaron KANTER - Somerville MA, US
Louise Clare KIRMAN - Swampscott MA, US
Changgang LOU - Somerville MA, US
Aimee Richardson USERA - Winchester MA, US
Ken YAMADA - Brookline MA, US
Jun YUAN - Boston MA, US
Frederic ZECRI - Brookline MA, US

International Classification:

A61K 47/54
A61K 38/095
A61K 38/08
A61K 38/16
A61K 38/17
A61K 38/18
A61K 38/22
A61K 45/06
C07C 55/02
C07C 55/22
C07C 57/02
C07C 57/18
C07C 59/245
C12N 15/113

Abstract:

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:

US Patent:

20180326079, Nov 15, 2018

Filed:

May 21, 2018

Appl. No.:

15/985060

Inventors:

- Basel, CH
Avirup BOSE - Marlborough MA, US
Alexandra Marshall BRUCE - Cambridge MA, US
Alokesh DUTTAROY - Marlborough MA, US
Chikwendu IBEBUNJO - Newton MA, US
Aaron KANTER - Somerville MA, US
Louise Clare KIRMAN - Swampscott MA, US
Changgang LOU - Somerville MA, US
Aimee Richardson USERA - Winchester MA, US
Ken YAMADA - Brookline MA, US
Jun YUAN - Boston MA, US
Frederic ZECRI - Brookline MA, US

International Classification:

A61K 47/54
C07C 55/02
A61K 38/08
C12N 15/113
C07C 59/245
C07C 57/18
C07C 57/02
C07C 55/22
A61K 45/06
A61K 38/22
A61K 38/18
A61K 38/17
A61K 38/16

Abstract:

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:

US Patent:

20160235810, Aug 18, 2016

Filed:

Oct 16, 2014

Appl. No.:

15/029689

Inventors:

Avirup BOSE - Cambridge MA, US
Alokesh DUTTAROY - Cambridge MA, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 38/17

Abstract:

The invention relates to methods of treating metabolic conditions, including type 2 diabetes mellitus, by administering prolactin-inducible protein (PIP) or fusion proteins, analogs or variants of PIP with altered or truncated PIP sequence, site-specific mutants, or chemically modified mutants including pharmaceutical properties comprising the same.

US Patent:

20160030585, Feb 4, 2016

Filed:

Jun 12, 2015

Appl. No.:

14/738272

Inventors:

David Weninger BARNES - Waban MA, US
Ken YAMADA - Brookline MA, US
Chikwendu IBEBUNJO - Newton MA, US
Alokesh DUTTAROY - Marlborough MA, US
Louis Clare KIRMAN - Swampscott MA, US
Alexandra Marshall BRUCE - Cambridge MA, US
Aimee Richardson USERA - Winchester MA, US
Frederic ZECRI - Brookline MA, US
Jun YUAN - Boston MA, US
Changgang LOU - Portage MI, US
Aaron KANTER - Somerville MA, US
Avirup BOSE - Marlborough MA, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 47/48
A61K 45/06
C07C 55/22
C07C 59/245
C07C 57/02
A61K 38/22
C07C 55/02
A61K 38/17
C12N 15/113
A61K 38/16
A61K 38/08
A61K 38/18
C07C 57/18

Abstract:

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: